DBV Technologies Peanut Allergy Drug Fails Key Study DBV Technologies Peanut Allergy Drug Fails Key Study

DBV Technologies SA said on October 20 its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news